RANI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RANI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Rani Therapeutics Holdings's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.49.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -33.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 5 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Rani Therapeutics Holdings was -10.80% per year. The lowest was -33.60% per year. And the median was -22.20% per year.
For the Biotechnology subindustry, Rani Therapeutics Holdings's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Rani Therapeutics Holdings's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
Rani Therapeutics Holdings (NAS:RANI) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Thank you for viewing the detailed overview of Rani Therapeutics Holdings's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Talat Imran | director, officer: CEO | C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131 |
South Cone Investments Limited Partnership | 10 percent owner | AVENIDA PRESIDENTE RIESCO 5711 OFICINA 1, LAS CONDES, SANTIAGO F3 7550000 |
Quiroga Cortes Isidoro Alfonso | 10 percent owner | 9020 N CAPITAL OF TEXAS HWY, SUITE I-260, AUSTIN TX 78759 |
Jean Luc Butel | director | ONE BAXTER PARKWAY, DEERFIELD IL 60015 |
Maulik Nanavaty | director | BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234 |
Kate Mckinley | officer: CHIEF BUSINESS OFFICER | C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131 |
Svai S Sanford | officer: CFO | C/O RANI THERAPEUTICS LLC, 2051 RINGWOOD AVE., SAN JOSE CA 95131 |
Eric Groen | officer: General Counsel | C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131 |
Mir Hashim | officer: Chief Scientific Officer | C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131 |
South Lake One Llc | 10 percent owner | 250 WEST 55TH STREET, NEW YORK NY 10019 |
Aequanimitas Limited Partnership | 10 percent owner | LEONEL AGUIRRE 1830, UNIT 101, MONTEVIDEO X3 11500 |
Mir A Imran | director | |
Andrew Farquharson | director | C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131 |
Laureen Debuono | director | |
Lisa Ann Rometty | director | C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131 |
From GuruFocus
By sperokesalga sperokesalga • 03-17-2023
By sperokesalga sperokesalga • 06-05-2023
By sperokesalga sperokesalga • 05-24-2023
By sperokesalga sperokesalga • 05-10-2023
By Value_Insider Value_Insider • 11-09-2022
By PurpleRose PurpleRose • 08-10-2022
By Marketwired • 09-18-2023
By Stock market mentor Stock market mentor • 01-05-2023
By PRNewswire • 01-09-2024
By GuruFocus Research • 11-08-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.